In a report released on March 25, Martin Roediger from Kepler Capital maintained a Buy rating on DSM-Firmenich AG (DSFIR – Research Report), with a price target of €144.00. The company’s ...

dsm-firmenich introduced Maxiren EVO, a coagulant enzyme designed to improved cheese production. Maxiren EVO is engineered with cutting-edge fermentation technology and targets alpha s-1 (αs1) casein ...